Recall of EpiPen Includes United States

Mylan Pharmaceuticals last week issued a recall of its EpiPen in seven countries. The first recall of the product that is injectable in emergencies involving allergies, did not include the United States.

However, Mylan late this week issued its latest recall which not just includes EpiPens that are sold in the U.S., it also involves the EpiPen Jr, a version for children.

The new recall includes EpiPens that were distributed from December 2015 to July 2016, but the pharmaceutical company did not make it clear the number of EpiPens that are affected.

The new generic version of the EpiPen is not amongst the voluntary recall and was deemed to be a replacement for the possibly defective brand name EpiPen.

The recall last week of EpiPens included Norway, Denmark, Australia and Japan and was due to complaints from a pair of consumers who said their EpiPen did not work when they had an allergic reaction.

However, both received medical attention that saved their lives.

The expanded recall was being initiated in the United States and would extend to other markets in Asia, Europe and North and South America, said Mylan in a prepared statement it released.

As of now, the additional markets mentioned by Mylan have not been released.

Patients have been told to visit the Mylan official website to see about replacements for EpiPens already purchased. The company was also encouraging its patients to keep their EpiPens nearby even if a replacement is not readily available.

The business practices of Mylan came under much scrutiny in 2016 after consumers begin to notice the price of the product was increasing rapidly.

After Mylan acquired the product back in 2007, the company raised its prices over 600% during the next 10 years.

Mylan has defended its actions through insisting quality control was amongst the different reasons for the hikes in prices.

CEO at Mylan Heather Bresch had to testify last year in front of the U.S. Congress. The company was also required to pay the U.S. government $465 million but did not have to admit to wrongdoing about its increase in prices.

President Donald Trump has made it a point to be critical of pharmaceutical companies since entering the White House saying they have been getting away with murder related to high prices.

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at


Leave a Reply

© 2006-2017 WKRB News.